Ivabradine: An intelligent drug for the treatment of ischemic heart disease

Molecules

Volumn 17, Issue 11, 2012, Pages 13592-13604

  Riccioni, Graziano ^a  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

Angina; Coronary artery disease; Fanny current; HCN channels; Heart rate; Ivabradine; Sino atrial node

Indexed keywords

BENZAZEPINE DERIVATIVE; IVABRADINE;

ANIMAL; CHEMICAL PHENOMENA; DRUG EFFECT; HEART; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; PATHOPHYSIOLOGY; REVIEW; SINUS NODE; STABLE ANGINA PECTORIS;

ANGINA, STABLE; ANIMALS; BENZAZEPINES; DEPRESSION, CHEMICAL; HEART; HEART RATE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; SINOATRIAL NODE;

EID: 84870197183     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules171113592     Document Type: Review

References (70)

1. Morrow, D.A.; Gersh, B.E.; Braunwald, E. Braunwald's Heart Disease, 7th ed.; Elsevier Saunders: Philadelphia, PA, USA, 2005; pp. 1281-1282.
2. O'Rourke, R.A.; O'Gara, P.; Douglas, J.S. Diagnosis and Management of Patients with Chronic Ischemic Heart Disease. In Hurst's The Heart, 11th ed.; McGraw Hill Medical Publishing Division: New York, NY, USA, 2004; pp. 1465-1472.
3. Kones, R.A. Recent advances in the management of chronic stable angina I: Approach to the patients, diagnosis, pathophysiology, risk stratification and gender disparities. Vasc. Health Risk Manag. 2010, 6, 635-656.
4. Kaski, J.C.; Arrebola-Moreno, A.; Dungu, J. Treatment strategies for chronic stable angina. Expert Opin. Pharmacother. 2011, 12, 2833-2844.
5. Barbuti, A.; Baruscotti, M.; DiFrancesco, D. The pacemaker current: From basics to the clinics. J. Cardiovasc. Electrophysiol. 2007, 18, 342-347.
6. Postea, O.; Biel, M. Exploring HCN channels as novel drug targets. Nat. Rev. Drug Discov. 2011, 10, 903-914.
7. Biel, M.; Schneider, A.; Wahl, C. Cardiac HCN channels: Structure, function, and modulation. Trends Cardiovasc. Med. 2002, 12, 206-212.
8. Reid, C.A.; Phillips, A.M.; Petrou, S. HCN channelopathies: Pathophysiology in genetic epilepsy and therapeutic implications. Br. J. Pharmacol. 2012, 165, 49-56.
9. DiFrancesco, D. The role of the funny current in pacemaker activity. Circ. Res. 2010, 106, 434-446.
10. DiFrancesco, D. Funny channel-based pacemaking. Heart Rhythm 2010, 7, 276-279.
11. Baruscotti, M.; Barbuti, A.; Bucchi, A. The cardiac pacemaker current. J. Mol. Cell. Cardiol. 2010, 48, 55-64.
12. DiFrancesco, D.; Borer, J.S. The funny current: Cellular basis for the control of heart rate. Drugs 2007, 67, 15-24.
13. Thollon, C.; Bedut, S.; Villeneuve, N. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br. J. Pharmacol. 2007, 150, 37-46.
14. Baruscotti, M.; Bottelli, G.; Milanesi, R.; DiFrancesco, J.C.; DiFrancesco, D. HCN-related channelopathies. Pflug. Arch. Eur. J. Physiol. 2010, 460, 405-415.
15. Biel, M.; Wahl-Schott, C.; Michalakis, S.; Zong, X. Hyperpolarization- activated cation channels: From genes to function. Physiol. Rev. 2009, 89, 847-885.
16. Wahl-Schott, C.; Biel, M. HCN channels: Structure, cellular regulation and physiological function. Cell. Mol. Life Sci. 2009, 66, 470-494.
17. Scicchitano, P.; Carbonara, S.; Ricci, G.; Mandurino, C.; Locorotondo, M.; Bulzis, G.; Gesualdo, M.; Zito, A.; Carbonara, R.; Dentamaro, I.; et al. HCN channels and heart rate. Molecules 2012, 17, 4225-4235.
18. f. Pflug. Arch. Eur. J. Physiol. 1998, 410, 139-142.
19. DiFrancesco, D.; Tromba, C. Muscarinic control of the hyperpolarization-activated current (If) in rabbit sino-atrial node myocytes. J. Physiol. 1988, 405, 493-510.
20. Summary of Product Characteristics. Procoralan™ (ivabradine hydrochloride). Servier Laboratories Ltd.: Cedex, France, October 2005. Available online: http://emc.medicines.org.uk (accessed on 27 November 2005).
21. European Public Assessment Report (EPAR): Scientific discussion for Procoralan. EMEA, London, UK, 17 November 2005. Available online: http://www.emea.eu.int (accessed on 18 November 2005).
22. Simon, L.; Ghaleh, B.; Puybasset, L.; Giudicelli, J.F.; Berdeaux, A. Coronary and haemodynamic effects of S16257, a new bradycardic agents, in resting and exercising conscious dogs. J. Pharmacol. Exp. Ther. 1995, 275, 579-586.
23. Ragueneau, I.; Laveillem, C.; Jochemsen, R.; Resplandy, G.; Funck-Brentano, C.; Jaillon, P. Pharmacokinetic - pharmacodynamic modelling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin. Pharmacol. Ther. 1998, 64, 192-203.
24. DiFrancesco, D. The contribution of pacemaker current (if) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J. Physiol. 1991, 34, 23-40.
25. f inhibition: A novel mechanism of action. Eur. Heart J. Suppl. 2003, 5, 19-25.
26. Tardif, J.C.; O'Meara, E.; Komajda, M.; Böhm, M.; Borer, J.S.; Ford, I.; Tavazzi, L.; Swedberg, K. SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur. Heart J. Suppl. 2011, 32, 2507-2515.
27. Brown, H.F.; DiFrancesco, D.; Noble, S.J. How does adrenaline accelerate the heart? Nature 1979, 280, 235-236.
28. f) pacemaker current in sheep cardiac Purkinie fibres. Eur. J. Pharmacol. 1990, 187, 241-256.
29. Franke, H.; Su, C.A.; Schumacher, K.; Seiberling, M. Clinical pharmacology of two specific bradycardiac agents. Eur. Heart J. 1987, 8, 91-98.
30. Kobinger, W.; Lillie, C.; Pichler, L. N-allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site. Naunyn Schmiedebergs Arch. Pharmacol. 1979, 306, 255-262.
31. f) in guinea-pig dissociated sinoatrial node cells. Br. J. Pharmacol. 1993, 110, 343-349.
32. f inhibition with ivabradine: Electrophysiological effects and safety. Drug Saf. 2008, 31, 95-107.
33. Koester, R.; Kaehler, J.; Meinertz, T. Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin. Res. Cardiol. 2011, 100, 121-128.
34. Riccioni, G. Ivabradine: Recent and potential applications in clinical practice. Expert Opin. Pharmacother. 2011, 12, 443-450.
35. f current inhibitor ivabradine: Safety considerations. Adv. Cardiol. 2006, 43, 79-96.
36. Swedberg, K.; Komajda, M.; Böhm, M.; Borer, J.S.; Ford, I.; Dubost-Brama, A.; Lerebours, G.; Tavazzi, L. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010, 376, 875-885.
37. Riccioni, G. Focus on ivabradine. Expert Rev. Cardiovasc. Ther. 2009, 7, 107-113.
38. Cervetto, L.; Demontis, G.C.; Gargini, C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br. J. Pharmacol. 2007, 150, 383-390.
39. Canet, E.; Lerebours, G.; Vilaine, J.P. Innovation in coronary artery disease and heart failure: Clinical benefits of pure heart rate reduction with ivabradine. Ann. N. Y. Acad. Sci. 2011, 1222, 90-99.
40. Tendera, M.; Talajic, M.; Robertson, M.; Tardif, J.C.; Ferrari, R.; Ford, I.; Steg, P.G.; Fox, K. BEAUTIFUL Investigators. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am. J. Cardiol. 2011, 107, 805-811.
41. Guaricci, A.I.; Schuijf, J.D.; Cademartiri, F.; Brunetti, N.D.; Montrone, D.; Maffei, E.; Tedeschi, C.; Ieva, R.; di Biase, L.; Midiri, M.; et al. Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. Int. J. Cardiol. 2012, 156, 28-33.
42. Calò, L.; Rebecchi, M.; Sette, A.; Martino, A.; de Ruvo, E.; Sciarra, L.; de Luca, L.; Zuccaro, L.M.; Giunta, G.; Ciccaglioni, A.; et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010, 7, 1318-1323.
43. Borer, J.S.; Tardif, J.C. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am. J. Cardiol. 2010, 105, 29-35.
44. Lage-Gallé, E.; Romero-Rodríguez, N.; Nevado-Portero, J.; Guisado-Rasco, A.; Sobrino-Márquez, M.; Machuca, M.G.; Fernández-Quero, M.; Campos-Pareja, A.; Ballesteros-Pradas, S.; Martínez-Martínez, A. Safety and effectiveness of ivabradine after cardiac transplantation. Transplant. Proc. 2010, 42, 3191-3192.
45. Camm, A.J.; Lau, C.P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R. D. 2003, 4, 83-89.
46. Kmecova, J.; Klimas, J. Heart rate correction of the QT duration in rats. Eur. J. Pharmacol. 2010, 641, 187-192.
47. Milliez, P.; Messaoudi, S.; Nehme, J.; Rodriguez, C.; Samuel, J.L.; Delcayre, C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, 435-441.
48. Summary of Product Characteristics (last update 16 February 2012). Available online: http://www.medicines.org.uk/EMC/medicine/17188/SPC/Procoralan/ (accessed on 18 June 2012).
49. Portolés, A.; Terleira, A.; Calvo, A.; Martínez, I.; Resplandy, G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: An open-label, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol. 2006, 46, 1188-1194.
50. Vlase, L.; Neag, M.; Popa, A.; Muntean, D.; Bâldea, I.; Leucuta, S.E. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J. Clin. Pharm. Ther. 2011, 36, 225-229.
51. Aboyans, V.; Criqui, M.H. Can we improve cardiovascular risk prediction beyond risk equations in the physician's office? J. Clin. Epidemiol. 2006, 59, 547-558.
52. Diaz, A.; Bourassa, M.G.; Guertin, M.C.; Tardif, J.C. Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005, 26, 967-974.
53. Fox, K.; Ford, I.; Steg, P.G.; Tendera, M.; Robertson, M.; Ferrari, R. Heart rate as a prognostic risk factors in patients with coronary artery diasease and left-ventricular systolic dysfuunction (BEAUTIFUL): A subgoup analysis of a randomised controlled trial. Lancet 2008, 372, 817-821.
54. Fox, K.; Borer, J.S.; Camm, A.J.; Danchin, N.; Ferrari, R.; Lopez-Sendon, J.L.; Steg, P.G.; Tardif, J.C.; Tavazzi, L.; Tendera, M.; et al. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol. 2007, 50, 823-830.
55. f inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003, 100, 149-155.
56. De Ferrari, G.M.; Mazzuero, A.; Agnesina, L.; Bertoletti, A.; Lettino, M.; Campana, C.; Schwartz, P.J.; Tavazzi, L. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur. J. Heart Fail. 2008, 10, 550-555.
57. Portolés, A.; Calvo, A.; Terleira, A.; Laredo, L.; Resplandy, G.; Gorostiaga, C.; Moreno, A. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: An open-label, randomized, crossover, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol. 2006, 46, 1195-1203.
58. f inhibitor, compared with atenolol in patients with chronic stable angina. Eur. Heart J. 2005, 26, 2529-2536.
59. Tardif, J.C. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases. Drugs Today 2008, 44, 171-181.
60. f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blockers therapy: A 4-month, randomized, placebo-controlled trial. Eur. Heart J. 2009, 30, 540-548.
61. Amosova, E.; Andrejev, E.; Zaderey, I.; Rudenko, U.; Ceconi, C.; Ferrari, R. Efficacy of ivabradine in combination with beta-blocker versus up titration of beta-blocker in patients with stable angina. Cardiovasc. Drugs Ther. 2011, 25, 531-537.
62. Werdan, K.; Ebelt, H.; Nuding, S.; Höpfner, F.; Hack, G.; Müller-Werdan, U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: Results from the ADDITIONS study. Clin. Res. Cardiol. 2012, 101, 365-373.
63. Riccioni, G.; Prencipe, G.A.; Benvenuto, A.; Masciocco, L.; Ventra, S.; Rizzo, U.; Russi, C.; Speziale, G. Ivabradine Improves All Aspects of Quality of Life Assessed with the 36-Item Short Form Health Survey in Subjects with Chronic Ischemic Heart Disease Compared with Beta-Blockers. Pharmacology 2012, doi:10.1159/000343631.
64. Fasullo, S.; Cannizzaro, S.; Maringhini, G.; Ganci, F.; Migliore, G.; Torres, D.; Sarullo, F.M.; Paterna, S.; di Pasquale, P. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: Preliminary findings. J. Card. Fail. 2009, 15, 856-863.
65. Post, F.; Münzel, T. Ivabradine - A new therapeutic option for cardiogenic shock? Herz 2009, 34, 224-229.
66. Nuding, S.; Enelt, H.; Hoke, R.S.; Krummenerl, A.; Wiemke, A.; Muller-Werdan, U.; Werdan, K. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I(f) (funny channel current) inhibitor ivabradine. MODI(f)Y trial. Clin. Res. Cardiol. 2011, 100, 915-923.
67. Heusch, G. Pleiotropic action(s) of the bradycardic agent ivabradine: Cardiovascular protection beyond heart rate reduction. Br. J. Pharmacol. 2008, 155, 970-971.
68. Heusch, G.; Skyschally, A.; Gres, P.; van Caster, P.; Schilawa, D.; Schulz, R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: Protection beyond heart rate reduction. Eur. Heart J. 2008, 29, 2265-2275.
69. Riccioni, G. Ivabradine: from molecular basis to clinical effectiveness. Adv. Ther. 2010, 27, 160-167.
70. Speranza, L.; Franceschelli, S.; Riccioni, G. The biological effects of ivabradine in cardiovascular disease. Molecules 2012, 17, 4924-4935.